Minor Cannabinoids Show Early Potential in Skin-Disease Research
A 2023 review in Molecules examined whether lesser-known cannabinoids could eventually contribute to treatments for acne, psoriasis, atopic dermatitis, and other skin conditions. The paper, “Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases—A Synthetic Review”, was written by Emilia Kwiecień and Dorota Kowalczuk of the Medical University of Lublin in Poland.
Rather than testing a new treatment in patients, the authors synthesized findings from existing scientific literature. Their review covered compounds that occur naturally in relatively small amounts in cannabis, including cannabidivarin (CBDV), cannabidiforol (CBDP), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabinol (CBN), cannabimovone (CBM), and cannabielsoin (CBE).
Across the studies they analyzed, these cannabinoids displayed a range of biological activities, including anti-inflammatory, antimicrobial, analgesic, antioxidant, and anti-itch effects. Some findings also suggested that cannabinoids may influence processes involved in acne, such as sebum production, sebocyte activity, and the release of inflammatory signaling molecules.
CBDV, for example, has been investigated for possible anti-inflammatory and anti-itch effects relevant to atopic dermatitis. The review also described preliminary work suggesting that CBDV may affect acne-related inflammation. CBC was linked in early research to anti-inflammatory and antioxidant activity, while THCV has attracted interest because of potential effects on sebum regulation and acne-associated bacteria. CBG, CBN, CBGA, CBM, and CBE were also identified as candidates for further investigation, although evidence for some of these compounds remains particularly sparse.
These findings are biologically plausible in part because the skin contains an active endocannabinoid system. Cannabinoid receptors and related signaling components are found in structures including keratinocytes, hair follicles, sebaceous glands, immune cells, and sensory nerves. This system is involved in skin-barrier function, cell growth and differentiation, immune responses, inflammation, pain, and itching.
However, the review does not establish that minor cannabinoids treat acne, psoriasis, eczema, or any other dermatological disease. Much of the underlying evidence comes from laboratory experiments, cell cultures, animal models, or small and limited human studies. Results can also vary substantially depending on the cannabinoid, dose, formulation, route of administration, and disease model. Earlier research on cannabinoids and skin inflammation has likewise emphasized that effects may be mixed and that controlled human studies are still needed; a review of cannabinoid mechanisms in skin inflammation describes both promising findings and important uncertainties.
Topical delivery could eventually offer a way to target the skin while limiting exposure elsewhere in the body, but formulation and absorption remain technical challenges. The quality and concentration of commercial cannabinoid products can also vary. In the United States, the Food and Drug Administration’s guidance on cannabis- and CBD-containing products notes that many products have not been evaluated for effectiveness, appropriate dosing, safety, or drug interactions.
The authors therefore call for better preclinical studies and well-designed clinical trials to determine which minor cannabinoids, if any, provide meaningful benefits, at what doses, and with what long-term risks. For now, the research supports continued scientific interest—not the conclusion that minor cannabinoids are established alternatives to standard dermatological treatments.
